Recently added

Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer

Prager, M.D., Gerald; taieb, julien; Fakih, Marwan; Ciardiello, Fortunato; Van Cutsem, Eric; Elez, Elena (Taylor & Francis, 2024)

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

Martins-Branco, Diogo; Rodrigues Beal, Juliana; Coleman, Niamh; Westphalen, Benedikt; Cardone, Claudia; Schram, Alison; GARRALDA, Elena; Mateo, Joaquin (Elsevier, 2024-11)

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT

Tarantino, Paolo; Tayob, Nabihah; DANG, CHAU; Yardley, Denise A.; Villacampa Javierre, Guillermo; Isakoff, Steven (American Society of Clinical Oncology, 2024-11-01)

Five latent factors underlie response to immunotherapy

Usset, Joseph; Huber, Axel Rosendahl; Andrianova, Maria A.; Batlle, Eduard; Lo Giacco, Deborah; Cuppen, Edwin; Elez, Elena; Gómez-Rey, Marina; Martínez-Jiménez, Francisco; MUÑOZ COUSELO, EVA; Tabernero, Josep; Vivancos, Ana; Carles, Joan; FELIP, ENRIQUETA (Nature Portfolio, 2024-10)

Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study

Guerrero-Zotano, Angel; Pérez-García, José Manuel; Ruiz-Borrego, Manuel; BERMEJO, BEGOÑA; Haba Rodríguez, Juan Rafael de la; Bellet Ezquerra, Meritxell; Gil Gil, Miguel J. (Elsevier, 2024-10)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT

Five latent factors underlie response to immunotherapy

Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer ﻿

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development ﻿

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT ﻿

Five latent factors underlie response to immunotherapy ﻿

Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study ﻿

Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT

Five latent factors underlie response to immunotherapy

Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study